1.55 0.02 (1.33%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 2.04 ![]() |
1-year : | 2.25 ![]() |
Resists | First : | 1.74 ![]() |
Second : | 1.92 ![]() |
Pivot price | 1.55 ![]() |
|||
Supports | First : | 1.45 | Second : | 1.2 |
MAs | MA(5) : | 1.52 ![]() |
MA(20) : | 1.55 ![]() |
MA(100) : | 1.81 ![]() |
MA(250) : | 2.19 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 26.2 ![]() |
D(3) : | 23.3 ![]() |
RSI | RSI(14): 46.3 ![]() |
|||
52-week | High : | 3.38 | Low : | 1.4 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CLLS ] has closed above bottom band by 47.2%. Bollinger Bands are 62.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.61 - 1.62 | 1.62 - 1.62 |
Low: | 1.5 - 1.51 | 1.51 - 1.51 |
Close: | 1.54 - 1.55 | 1.55 - 1.56 |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Wed, 05 Feb 2025
Cellectis S.A. (NASDAQ:CLLS) Short Interest Update - MarketBeat
Sat, 18 Jan 2025
Short Interest in Cellectis S.A. (NASDAQ:CLLS) Expands By 59.7% - MarketBeat
Tue, 07 Jan 2025
Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't? - Nasdaq
Sun, 29 Dec 2024
Analysts Predict 400% Upside Potential for This Penny Stock - GuruFocus.com
Thu, 12 Dec 2024
Cellectis: Poised To Start Answering Questions In 2025 (NASDAQ:CLLS) - Seeking Alpha
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 100 (M) |
Shares Float | 71 (M) |
Held by Insiders | 3.8 (%) |
Held by Institutions | 15.3 (%) |
Shares Short | 165 (K) |
Shares Short P.Month | 127 (K) |
EPS | -1.16 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.28 |
Profit Margin | -234.4 % |
Operating Margin | -59.7 % |
Return on Assets (ttm) | -16.1 % |
Return on Equity (ttm) | -82.2 % |
Qtrly Rev. Growth | 998 % |
Gross Profit (p.s.) | 0.35 |
Sales Per Share | 0.36 |
EBITDA (p.s.) | -0.68 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 63 (M) |
Levered Free Cash Flow | -14 (M) |
PE Ratio | -1.34 |
PEG Ratio | 0 |
Price to Book value | 1.2 |
Price to Sales | 4.3 |
Price to Cash Flow | 2.47 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |